CNETS is happy to announce that BC Cancer will now reimburse LUTATHERA for the approved indication.
The BC Cancer Benefit Drug List, Published March 2021, Tumour Site: Gastrointestinal
Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Midgut Neuroendocrine Tumours.
The BC Cancer Protocol Summary for Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Midgut Neuroendocrine Tumours